文献速递肿瘤 PET/CT

68Ga-PSMA-11 PET在原发前列腺癌中的摄取相关组织病理与免疫组化PSMA表达模式研究

What's behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-08-13

该研究分析了62例术前行68Ga-PSMA-11 PET的前列腺癌根治术标本,将WHO/ISUP分级、生长模式、肿瘤面积与直径及PSMA免疫组化异质性、强度、阴性面积(PSMA%neg)与对应SUVmax关联。结果显示PSMA%neg、浸润性生长、较小肿瘤及WHO/ISUP 2级与较低SUVmax相关,20% PSMA%neg为预测阴性PSMA-PET的最佳阈值。

要点

  • PSMA%neg≥20%与68Ga-PSMA-11 PET阴性扫描相关,灵敏度89%、特异度86%。
  • 浸润性生长模式、较小肿瘤面积与直径及WHO/ISUP 2级与较低SUVmax显著相关。
  • 肿瘤PSMA%neg和生长模式是PSMA-PET阴性扫描的独立预测因素。

核心结论

  • PSMA%neg、浸润性生长模式、较小肿瘤尺寸和WHO/ISUP 2级与前列腺癌中较低的68Ga-PSMA-11摄取相关。

研究设计与样本

  • 回顾性分析2016至2018年间62例术前接受68Ga-PSMA-11 PET的前列腺癌根治术标本,多学科关联组织病理与免疫组化参数和空间对应SUVmax。

主要发现

  • 所有肿瘤均显示中等至强膜性(2-3+)和弱至强胞质(1-3+)PSMA表达。
  • PSMA%neg、浸润性生长模式、较小肿瘤面积和直径及WHO/ISUP 2级与较低SUVmax显著相关。
  • ROC曲线显示20% PSMA%neg为预测阴性PSMA-PET扫描的最佳截断值,灵敏度89%、特异度86%、AUC 0.923。
  • 多因素logistic回归显示肿瘤PSMA%neg(p<0.01,OR=9.629)和生长模式(p=0.0497,OR=306.537)为阴性PSMA-PET扫描的显著预测因素。

关键数值与推荐

  • PSMA%neg截断值20%用于预测阴性PSMA-PET扫描,灵敏度89%、特异度86%、AUC 0.923。
  • 多因素分析中PSMA%neg的p<0.01、OR=9.629,生长模式的p=0.0497、OR=306.537。

临床怎么用

  • 对于PSMA%neg≥20%或浸润性生长模式的前列腺癌,68Ga-PSMA-11 PET可能出现假阴性,需结合活检病理综合判断。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prostate-specific membrane antigen (PSMA-) PET has become a promising tool in staging and restaging of prostate carcinoma (PCa). However, specific primary tumour features might impact accuracy of PSMA-PET for PCa detection. We investigated histopathological parameters and immunohistochemical PSMA expression patterns on radical prostatectomy (RPE) specimens and correlated them to the corresponding 68Ga-PSMA-11-PET examinations. METHODS: RPE specimens of 62 patients with preoperative 68Ga-PSMA-11-PET between 2016 and 2018 were analysed. WHO/ISUP grade groups, growth pattern (expansive vs. infiltrative), tumour area and diameter as well as immunohistochemical PSMA heterogeneity, intensity and negative tumour area (PSMA%neg) were correlated with spatially corresponding SUVmax on 68Ga-PSMA-11-PET in a multidisciplinary analysis. RESULTS: All tumours showed medium to strong membranous (2-3 +) and weak to strong cytoplasmic (1-3 +) PSMA expression. Heterogeneously expressed PSMA was found in 38 cases (61%). Twenty-five cases (40%) showed at least 5% and up to 80% PSMA%neg. PSMA%neg, infiltrative growth pattern, smaller tumour area and diameter and WHO/ISUP grade group 2 significantly correlated with lower SUVmax values. A ROC curve analysis revealed 20% PSMA%neg as an optimal cutoff with the highest sensitivity and specificity (89% and 86%, AUC 0.923) for a negative PSMA-PET scan. A multiple logistic regression model revealed tumoural PSMA%neg (p < 0.01, OR = 9.629) and growth pattern (p = 0.0497, OR = 306.537) as significant predictors for a negative PSMA-PET scan. CONCLUSIONS: We describe PSMA%neg, infiltrative growth pattern, smaller tumour size and WHO/ISUP grade group 2 as parameters associated with a lower 68Ga-PSMA-11 uptake in prostate cancer. These findings can serve as fundament for future biopsy-based biomarker development to enable an individualized, tumour-adapted imaging approach.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Rüschoff JH, Ferraro DA, Muehlematter UJ, et al. What's behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns. Eur J Nucl Med Mol Imaging. 2021. PMID: 34386839. doi:10.1007/s00259-021-05501-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。